Literature DB >> 4076392

Leishmania donovani: amastigote inhibition and mode of action of berberine.

A K Ghosh, F K Bhattacharyya, D K Ghosh.   

Abstract

Berberine, an alkaloid from Berberis aristata Linnaeus, may be a useful drug for the treatment of visceral leishmaniasis. In both the 8-day and long-term models of Leishmania donovani infection in hamsters, it markedly diminished the parasitic load and proved to be less toxic than pentamidine. It rapidly improved the hematological picture of infected animals. Like pentamidine, it inhibited in vitro multiplication of amastigotes in macrophage culture and their transformation to promastigotes in cell free culture. Manometric studies showed that both drugs had inhibitory action on both the endogenous and the glucose-stimulated respiration of amastigotes. They inhibited incorporation of [14C]adenine, [14C]uracil, and [3H]thymidine into nucleic acids, and of [14C]leucine into the protein of amastigotes, indicating an inhibitory action on macromolecular biosynthesis. They also decreased deoxyglucose uptake. Using spectrophotometric, spectrofluorimetric, and circular dichroism techniques, berberine was found to interact in vitro with nuclear DNA from L. donovani promastigotes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4076392     DOI: 10.1016/0014-4894(85)90047-5

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  20 in total

Review 1.  Biological screening of natural products and drug innovation in China.

Authors:  Ming-Wei Wang; Xiaojiang Hao; Kaixian Chen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-06-29       Impact factor: 6.237

Review 2.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

3.  Cell type-specific localization of transcripts encoding nine consecutive enzymes involved in protoberberine alkaloid biosynthesis.

Authors:  Nailish Samanani; Sang-Un Park; Peter J Facchini
Journal:  Plant Cell       Date:  2005-02-18       Impact factor: 11.277

4.  Berberine inhibits arylamine N-acetyltransferase activity and gene expression in Salmonella typhi.

Authors:  Lii-Tzu Wu; Mei-Fen Tsou; Chin-Chin Ho; Jing-Yuan Chuang; Hsiu-Maan Kuo; Jing-Gung Chung
Journal:  Curr Microbiol       Date:  2005-08-02       Impact factor: 2.188

5.  Identification of new antigens in visceral leishmaniasis by expression cloning and immunoblotting with sera of kala-azar patients from Bihar, India.

Authors:  Stephan M Theinert; Rajatava Basu; Michael Forgber; Syamal Roy; Shyam Sundar; Peter Walden
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes.

Authors:  F Afrin; N Ali
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

7.  9-O-Ethyl-berberrubinium iodide monohydrate.

Authors:  Peter Grundt; Jennifer Pernat; Bogdana Krivogorsky; Melanie A Halverson; Steven M Berry
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-09-18

8.  Berberine derivatives as antileishmanial drugs.

Authors:  J L Vennerstrom; J K Lovelace; V B Waits; W L Hanson; D L Klayman
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

9.  Dose-dependent effects of berberine on cell cycle pause and apoptosis in Balb/c 3T3 cells.

Authors:  I W Yang; C C Chou; B Y Yung
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

10.  Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani.

Authors:  M Chen; S B Christensen; T G Theander; A Kharazmi
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.